SE8704248D0 - Medical use - Google Patents

Medical use

Info

Publication number
SE8704248D0
SE8704248D0 SE8704248A SE8704248A SE8704248D0 SE 8704248 D0 SE8704248 D0 SE 8704248D0 SE 8704248 A SE8704248 A SE 8704248A SE 8704248 A SE8704248 A SE 8704248A SE 8704248 D0 SE8704248 D0 SE 8704248D0
Authority
SE
Sweden
Prior art keywords
bone
loss
diseases
medical use
hypercalcinemia
Prior art date
Application number
SE8704248A
Other languages
English (en)
Swedish (sv)
Inventor
I Starke
B Wallmark
K Veenenen
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haessle Ab filed Critical Haessle Ab
Priority to SE8704248A priority Critical patent/SE8704248D0/xx
Publication of SE8704248D0 publication Critical patent/SE8704248D0/xx
Priority to JP63508894A priority patent/JPH02501929A/ja
Priority to PCT/SE1988/000576 priority patent/WO1989003833A1/fr
Priority to HU886708A priority patent/HU203663B/hu
Priority to KR1019890701209A priority patent/KR890701587A/ko
Priority to AU26203/88A priority patent/AU2620388A/en
Priority to EP88909620A priority patent/EP0339071A1/fr
Priority to IL88205A priority patent/IL88205A0/xx
Priority to DK322189A priority patent/DK322189A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8704248A 1987-10-30 1987-10-30 Medical use SE8704248D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE8704248A SE8704248D0 (sv) 1987-10-30 1987-10-30 Medical use
JP63508894A JPH02501929A (ja) 1987-10-30 1988-10-27 医学的使用
PCT/SE1988/000576 WO1989003833A1 (fr) 1987-10-30 1988-10-27 IMIDAZO(1,2-a)(PYRIDAZINES OU PYRAZINES) PERMETTANT LE TRAITEMENT DE MALADIES RELATIVES A LA PERTE OSSEUSE
HU886708A HU203663B (en) 1987-10-30 1988-10-27 Process for producing pharmaceutical composition against osteoporosis containing imidazo(1,2)pyridine derivatives
KR1019890701209A KR890701587A (ko) 1987-10-30 1988-10-27 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리
AU26203/88A AU2620388A (en) 1987-10-30 1988-10-27 Imidazo(1,2-a)(pyridazines or pyrazines) for treatment of diseases related to bone loss
EP88909620A EP0339071A1 (fr) 1987-10-30 1988-10-27 IMIDAZO(1,2-a)(PYRIDAZINES OU PYRAZINES) PERMETTANT LE TRAITEMENT DE MALADIES RELATIVES A LA PERTE OSSEUSE
IL88205A IL88205A0 (en) 1987-10-30 1988-10-28 Novel pyridine compounds and compositions for the treatment of osteoporosis
DK322189A DK322189A (da) 1987-10-30 1989-06-28 Imidazo(1,2-a)-(pyridaziner eller pyraziner) til behandling af sygdomme med relation til knogletab

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8704248A SE8704248D0 (sv) 1987-10-30 1987-10-30 Medical use

Publications (1)

Publication Number Publication Date
SE8704248D0 true SE8704248D0 (sv) 1987-10-30

Family

ID=20370069

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8704248A SE8704248D0 (sv) 1987-10-30 1987-10-30 Medical use

Country Status (9)

Country Link
EP (1) EP0339071A1 (fr)
JP (1) JPH02501929A (fr)
KR (1) KR890701587A (fr)
AU (1) AU2620388A (fr)
DK (1) DK322189A (fr)
HU (1) HU203663B (fr)
IL (1) IL88205A0 (fr)
SE (1) SE8704248D0 (fr)
WO (1) WO1989003833A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87988B (pt) * 1987-07-16 1995-05-04 Byk Gulden Lomberg Chem Fab Processo para a preparacao de diazois e de composicoes farmaceuticas que os contem
US5081253A (en) * 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
US5464843A (en) * 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
AU5348396A (en) * 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
GB9518552D0 (en) * 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
WO2007028051A2 (fr) 2005-09-02 2007-03-08 Abbott Laboratories Nouveaux heterocycles a base imidazo
CA2822357A1 (fr) 2010-12-22 2012-06-28 Abbvie Inc. Inhibiteurs de l'hepatite c et leurs utilisations
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CA2914100A1 (fr) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridines a substitution 3-aryle et leur utilisation
MX2016000258A (es) 2013-07-10 2016-04-28 Bayer Pharma AG Bencil-1h-pirazolo[3,4-b]piridinas y su uso.
US9688699B2 (en) 2014-02-19 2017-06-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
CN106715426A (zh) 2014-03-21 2017-05-24 拜耳医药股份有限公司 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
EP3137463A1 (fr) 2014-05-02 2017-03-08 Bayer Pharma Aktiengesellschaft Énantiomères du n-(2-amino-5-fluor-2-méthylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-méthylimidazo[1,2-a]pyridine-3-carboxamide et de ses dérivés difluorés et trifluorés pour traiter des maladies cardiovasculaires
EP3137465A1 (fr) * 2014-05-02 2017-03-08 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine carboxamides substitués par chlore en position 6 et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
JP2017514899A (ja) * 2014-05-02 2017-06-08 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロシクリル−およびヘテロアリール−置換イミダゾ［１，２−ａ］ピリジンおよびその使用
EP3227286B1 (fr) 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Pyrazolo[1,5-a]pyridines et imidazo[1,2-a]pyrazines substituées et leur utilisation
JP2017536396A (ja) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロアリール置換イミダゾ［１，２−ａ］ピリジンおよびその使用
US10150773B2 (en) 2015-02-05 2018-12-11 Bayer Pharma Aktiengesellschaft N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases
JP2018505885A (ja) 2015-02-05 2018-03-01 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロ［１，５−ａ］−ピリジン−３−カルボキサミドおよびその使用
WO2018184976A1 (fr) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-carboxamides substitués et leur utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4468400A (en) * 1982-12-20 1984-08-28 Schering Corporation Antiulcer tricyclic imidazo [1,2-a]pyridines
DE3446778A1 (de) * 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
EP0228006A1 (fr) * 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Composés d'imidazopyridine et procédés pour leur préparation

Also Published As

Publication number Publication date
DK322189D0 (da) 1989-06-28
EP0339071A1 (fr) 1989-11-02
KR890701587A (ko) 1989-12-21
AU2620388A (en) 1989-05-23
WO1989003833A1 (fr) 1989-05-05
DK322189A (da) 1989-06-28
JPH02501929A (ja) 1990-06-28
HU203663B (en) 1991-09-30
IL88205A0 (en) 1989-06-30
HUT51138A (en) 1990-04-28

Similar Documents

Publication Publication Date Title
SE8704248D0 (sv) Medical use
ES555147A0 (es) Un procedimiento para la produccion de un compuesto de tiazolidindiona hipoglicemico
MX9203543A (es) Medicamento.
ITFI910071U1 (it) Piastra per osso per la porzione distale dell'omero.
EP0395441A3 (fr) Agent pour le traitement de l'ostéo-arthrite
ES2052028T3 (es) Un metodo para preparar compuestos diarilicos anti-ateroscleroticos.
IL82084A0 (en) 1,4-diazepines,their preparation and pharmaceutical compositions containing them
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
MY103790A (en) Novel compound for the treatment of several bone affecting diseases
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
EP0269311A3 (fr) Méthodes pour le traitement des maladies osseuses par l'administration des inhibiteurs de la cystéine-protéinase
SE8903529D0 (sv) Medical use
ZA863382B (en) Quinolylglycinamide derivatives,the process for preparation thereof and their therapeutic application as psychotropic drugs
SE8704436D0 (sv) Anvendning av antisekretoriska substanser for nya indikationer
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ZA879280B (en) Basically substituted phenylacetonitriles,their preparation and drugs containing these compounds
IL79910A (en) 5,7-dihydro-6-(thi)oxopyrrolo(2,3-f)benzimidazole,-benzothiazole and-benzoxazoles,6-imines thereof,their preparation and pharmaceutical compositions containing them
SE9402001D0 (sv) Pyridylbisphosphonates for use as a therapeutical agent
PT99864A (pt) Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
IT8219482A0 (it) Composizione farmaceutica per la cura di affezioni della cavita'orale.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
HU903092D0 (en) Process for the preparation of buten-carboxylic acid derivatives and pharmaceutical compositions containing such compounds
GR861013B (en) Process for the preparation of triazole derivatives
CS22891A2 (en) Application of benzylphosphonic acid's derivatives for treatment of virusinduced diseases
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit